With the increased global burden of immunocompromised diseases such as HIV, TB and COVID-19, opportunistic fungal infections have predominantly increased over the past few decades. Invasive and widespread fungal disease (IFD) has been linked to a variety of rare fungal diseases in different parts of the world ...
With the increased global burden of immunocompromised diseases such as HIV, TB and COVID-19, opportunistic fungal infections have predominantly increased over the past few decades. Invasive and widespread fungal disease (IFD) has been linked to a variety of rare fungal diseases in different parts of the world Despite the improvement of antifungal therapies over the last 30 years, the phenomenon of antifungal resistance is still a major concern in clinical practice. The establishment of antifungal stewardship programs in clinical settings and the inclusion of antifungal susceptibility testing, and therapeutic drug monitoring practices in the clinics can minimize the emergence of drug-resistant fungi. New antifungal drugs featuring promising therapeutic profiles have great promise to treat drug-resistant fungi in the clinical setting. Mitigating antifungal tolerance, a prelude to the emergence of resistance, also requires the development of effective and fungal-specific adjuvants to be used in combination with systemic antifungals. New methods of understanding fungal diseases through early diagnosis would mitigate mortality and provide better treatment. This Special issue aims to understand recent trends in fungal infections for understanding diagnostics, therapeutics, and drug resistance.
Given the growing significance and awareness as well as the recently emerging data, the aim of this Special Issue is to highlight the recent advance that has been undertaken towards tackling antifungal resistance viz., new diagnostics, improved treatment via different approaches, synergistic effect obtained by the combination of antifungals and or using natural products to reducing toxicity. The issue will also focus on development of new formulations for antifungal agents. In addition, modifications to the chemical structures of traditional antifungals with improved activity and pharmacokinetic parameters will be of wide interest.
We welcome articles of all categories on the following themes, but not limited to:
• Invasive fungal infections
• Novel Antifungal drugs
• Natural Products as possible antifungals
• Drug resistance and mechanisms
• Traditional and non-traditional approaches to combat drug resistance
• New formulations
• Molecular diagnostics of fungal infections
• Current antifungal therapeutics and biomarkers
Diagnostics, Biomarker, Drug Resistance, Alternative Therapy
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.